Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

已完结 100 由 Aixuexi 发布于 2026/2/24 9:25:11

DOI:10.1200/jco-25-01210
作者：Philipp Harter,Frederik Marmé,Andrés Redondo,Alexander Reuss,Kristina Lindemann,Christian Kurzeder,Els Van Nieuwenhuysen,Christian Marth,Klaus Pietzner,Isabelle Ray-Coquard,Carmen Garcia-Duran,Goda
文献类型：期刊论文
补充材料：只需要正文

American Society of Clinical Oncology (ASCO)

Abstract：PURPOSE To evaluate atezolizumab combined with bevacizumab and non-platinum-based chemotherapy for recurrent ovarian cancer. METHODS The double-blind randomized phase III AGO-OVAR 2.29/

应助信息

16小时前

Tony

77f25e55112011f1846e34735aa3bc31.pdf 已采纳

16小时前

Book学术机器人

2026/2/24 9:25:11 未找到该文献，机器人已退出，请等待人工下载

2026/2/24 9:25:11 Book学术AI机器人收到请求，开始寻找文献

2026/2/24 9:25:11 已向机器人发送请求

16小时前

Aixuexi 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网光催化和电化学在连续流合成中的研究进展